|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feller L and Lemmer J: Oral squamous cell
carcinoma: Epidemiology, clinical presentation and treatment. J
Cancer Ther. 3:263–268. 2012. View Article : Google Scholar
|
|
3
|
Rodrigues MFSD, Miguita L, De Andrade NP,
Heguedusch D, Rodini CO, Moyses RA, Toporcov TN, Gama RR, Tajara EE
and Nunes FD: GLI3 knockdown decreases stemness, cell proliferation
and invasion in oral squamous cell carcinoma. Int J Oncol.
53:2458–2472. 2018.PubMed/NCBI
|
|
4
|
Zhang L, Meng X, Zhu XW, Yang DC, Chen R,
Jiang Y and Xu T: Long non-coding RNAs in oral squamous cell
carcinoma: Biologic function, mechanisms and clinical implications.
Mol Cancer. 18:1022019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sakata J, Hirosue A, Yoshida R, Kawahara
K, Matsuoka Y, Yamamoto T, Nakamoto M, Hirayama M, Takahashi N,
Nakamura T, et al: HMGA2 contributes to distant metastasis and poor
prognosis by promoting angiogenesis in oral squamous cell
carcinoma. Int J Mol Sci. 20:202019. View Article : Google Scholar
|
|
6
|
Hiemer SE, Zhang L, Kartha VK, Packer TS,
Almershed M, Noonan V, Kukuruzinska M, Bais MV, Monti S and Varelas
X: A YAP/TAZ-regulated molecular signature is associated with oral
squamous cell carcinoma. Mol Cancer Res. 13:957–968. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li SY, Hu JA and Wang HM: Expression of
Yes-associated protein 1 gene and protein in oral squamous cell
carcinoma. Chin Med J (Engl). 126:655–658. 2013.PubMed/NCBI
|
|
8
|
Chen X, Gu W, Wang Q, Fu X, Wang Y, Xu X
and Wen Y: C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in
OSCC. Oncotarget. 9:668–679. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshikawa K, Noguchi K, Nakano Y, Yamamura
M, Takaoka K, Hashimoto-Tamaoki T and Kishimoto H: The Hippo
pathway transcriptional co-activator, YAP, confers resistance to
cisplatin in human oral squamous cell carcinoma. Int J Oncol.
46:2364–2370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng G, Xun W, Wei K, Yang Y and Shen H:
MicroRNA-27a-3p regulates epithelial to mesenchymal transition via
targeting YAP1 in oral squamous cell carcinoma cells. Oncol Rep.
36:1475–1482. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong C, Wei KJ, Zhang WB, Sun H, Pan HY
and Zhang L: LATS2 induced by TNF-alpha and inhibited cell
proliferation and invasion by phosphorylating YAP in oral squamous
cell carcinoma. J Oral Pathol Med. 44:475–481. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fan H, Tian H, Cheng X, Chen Y, Liang S,
Zhang Z, Liao Y and Xu P: Aberrant Kank1 expression regulates YAP
to promote apoptosis and inhibit proliferation in OSCC. J Cell
Physiol. 235:1850–1865. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakatani K, Maehama T, Nishio M, Goto H,
Kato W, Omori H, Miyachi Y, Togashi H, Shimono Y and Suzuki A:
Targeting the Hippo signalling pathway for cancer treatment. J
Biochem. 161:237–244. 2017.PubMed/NCBI
|
|
14
|
Witters LA: The blooming of the French
lilac. J Clin Invest. 108:1105–1107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rêgo DF, Pavan LM, Elias ST, De Luca Canto
G and Guerra EN: Effects of metformin on head and neck cancer: A
systematic review. Oral Oncol. 51:416–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang PH, Yeh KY, Wang CH, Chen EY, Yang
SW, Chou WC and Hsieh JC: Impact of metformin on patients with
advanced head and neck cancer undergoing concurrent
chemoradiotherapy. Head Neck. 39:1573–1577. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen
F: In vitro and in vivo anti-tumor effect of metformin as a novel
therapeutic agent in human oral squamous cell carcinoma. BMC
Cancer. 12:5172012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen CH, Tsai HT, Chuang HC, Shiu LY, Su
LJ, Chiu TJ, Luo SD, Fang FM, Huang CC and Chien CY: Metformin
disrupts malignant behavior of oral squamous cell carcinoma via a
novel signaling involving Late SV40 factor/Aurora-A. Sci Rep.
7:13582017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi X, Xu W, Xie J, Wang Y, Han S, Wei Z,
Ni Y, Dong Y and Han W: Metformin sensitizes the response of oral
squamous cell carcinoma to cisplatin treatment through inhibition
of NF-κB/HIF-1α signal axis. Sci Rep. 6:357882016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jivan R, Peres J, Damelin LH, Wadee R,
Veale RB, Prince S and Mavri-Damelin D: Disulfiram with or without
metformin inhibits oesophageal squamous cell carcinoma in vivo.
Cancer Lett. 417:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harada K, Ferdous T, Harada T and Ueyama
Y: Metformin in combination with 5-fluorouracil suppresses tumor
growth by inhibiting the Warburg effect in human oral squamous cell
carcinoma. Int J Oncol. 49:276–284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alalem M, Ray A and Ray BK: Metformin
induces degradation of mTOR protein in breast cancer cells. Cancer
Med. 5:3194–3204. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ben Sahra I, Regazzetti C, Robert G,
Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF,
Giorgetti-Peraldi S and Bost F: Metformin, independent of AMPK,
induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer
Res. 71:4366–4372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Akinyeke T, Matsumura S, Wang X, Wu Y,
Schalfer ED, Saxena A, Yan W, Logan SK and Li X: Metformin targets
c-MYC oncogene to prevent prostate cancer. Carcinogenesis.
34:2823–2832. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Javeshghani S, Zakikhani M, Austin S,
Bazile M, Blouin MJ, Topisirovic I, St-Pierre J and Pollak MN:
Carbon source and myc expression influence the antiproliferative
actions of metformin. Cancer Res. 72:6257–6267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang N and Pende M: YAP enters the mTOR
pathway to promote tuberous sclerosis complex. Mol Cell Oncol.
2:e9981002015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang J, Chang W, Fu Y, Gao Y, Zhao C,
Zhang X and Zhang S: SAV1 represses the development of human
colorectal cancer by regulating the Akt-mTOR pathway in a
YAP-dependent manner. Cell Prolif. 50:502017. View Article : Google Scholar
|
|
30
|
Hansen CG, Ng YL, Lam WL, Plouffe SW and
Guan KL: The Hippo pathway effectors YAP and TAZ promote cell
growth by modulating amino acid signaling to mTORC1. Cell Res.
25:1299–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Choi W, Kim J, Park J, Lee DH, Hwang D,
Kim JH, Ashktorab H, Smoot D, Kim SY, Choi C, et al: YAP/TAZ
initiates gastric tumorigenesis via upregulation of MYC. Cancer
Res. 78:3306–3320. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cai J, Song X, Wang W, Watnick T, Pei Y,
Qian F and Pan D: A RhoA-YAP-c-Myc signaling axis promotes the
development of polycystic kidney disease. Genes Dev. 32:781–793.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xiao W, Wang J, Ou C, Zhang Y, Ma L, Weng
W, Pan Q and Sun F: Mutual interaction between YAP and c-Myc is
critical for carcinogenesis in liver cancer. Biochem Biophys Res
Commun. 439:167–172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Turato C, Cannito S, Simonato D, Villano
G, Morello E, Terrin L, Quarta S, Biasiolo A, Ruvoletto M, Martini
A, et al: SerpinB3 and Yap Interplay Increases Myc Oncogenic
Activity. Sci Rep. 5:177012015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lulla AR, Slifker MJ, Zhou Y, Lev A,
Einarson MB, Dicker DT and El-Deiry WS: miR-6883 family miRNAs
target CDK4/6 to induce G1 phase cell-cycle arrest in colon cancer
cells. Cancer Res. 77:6902–6913. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gulappa T, Reddy RS, Suman S, Nyakeriga AM
and Damodaran C: Molecular interplay between cdk4 and p21 dictates
G0/G1 cell cycle arrest in prostate cancer cells. Cancer Lett.
337:177–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ren F, Zhang L and Jiang J: Hippo
signaling regulates Yorkie nuclear localization and activity
through 14-3-3 dependent and independent mechanisms. Dev Biol.
337:303–312. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park YY, Sohn BH, Johnson RL, Kang MH, Kim
SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, et al:
Yes-associated protein 1 and transcriptional coactivator with
PDZ-binding motif activate the mammalian target of rapamycin
complex 1 pathway by regulating amino acid transporters in
hepatocellular carcinoma. Hepatology. 63:159–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tumaneng K, Schlegelmilch K, Russell RC,
Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo
FD and Guan KL: YAP mediates crosstalk between the Hippo and
PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol.
14:1322–1329. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Safe S, Nair V and Karki K:
Metformin-induced anticancer activities: Recent insights. Biol
Chem. 399:321–335. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mynhardt C, Damelin LH, Jivan R, Peres J,
Prince S, Veale RB and Mavri-Damelin D: Metformin-induced
alterations in nucleotide metabolism cause 5-fluorouracil
resistance but gemcitabine susceptibility in oesophageal squamous
cell carcinoma. J Cell Biochem. 119:1193–1203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Damelin LH, Jivan R, Veale RB, Rousseau AL
and Mavri-Damelin D: Metformin induces an intracellular reductive
state that protects oesophageal squamous cell carcinoma cells
against cisplatin but not copper-bis(thiosemicarbazones). BMC
Cancer. 14:3142014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Henney JE: From the Food and Drug
Administration. JAMA. 283:27792000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang B, Shao W, Shi Y, Liao J, Chen X and
Wang C: Verteporfin induced SUMOylation of YAP1 in endometrial
cancer. Am J Cancer Res. 10:1207–1217. 2020.PubMed/NCBI
|
|
48
|
Lui JW, Xiao S, Ogomori K, Hammarstedt JE,
Little EC and Lang D: The efficiency of verteporfin as a
therapeutic option in pre-clinical models of melanoma. J Cancer.
10:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong
J, Sun X and Li J: Verteporfin suppresses cell survival,
angiogenesis and vasculogenic mimicry of pancreatic ductal
adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci.
108:478–487. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo
W, Lu Y and Mills GB: Verteporfin inhibits YAP function through
up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J
Cancer Res. 6:27–37. 2015.PubMed/NCBI
|
|
51
|
Meng Z, Moroishi T and Guan KL: Mechanisms
of Hippo pathway regulation. Genes Dev. 30:1–17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhao B, Li L, Tumaneng K, Wang CY and Guan
KL: A coordinated phosphorylation by Lats and CK1 regulates YAP
stability through SCF(beta-TRCP). Genes Dev. 24:72–85. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mossmann D, Park S and Hall MN: mTOR
signalling and cellular metabolism are mutual determinants in
cancer. Nat Rev Cancer. 18:744–757. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li SH, Chien CY, Huang WT, Luo SD, Su YY,
Tien WY, Lan YC and Chen CH: Prognostic significance and function
of mammalian target of rapamycin in tongue squamous cell carcinoma.
Sci Rep. 7:81782017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Su W, Wang Y, Wang F, Zhang B, Zhang H,
Shen Y and Yang H: Circular RNA hsa_circ_0007059 indicates
prognosis and influences malignant behavior via AKT/mTOR in oral
squamous cell carcinoma. J Cell Physiol. 234:15156–15166. 2019.
View Article : Google Scholar
|
|
56
|
Zhang X, Liu N, Ma D, Liu L, Jiang L, Zhou
Y, Zeng X, Li J and Chen Q: Receptor for activated C kinase 1
(RACK1) promotes the progression of OSCC via the AKT/mTOR pathway.
Int J Oncol. 49:539–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Artinian N, Cloninger C, Holmes B,
Benavides-Serrato A, Bashir T and Gera J: Phosphorylation of the
Hippo pathway component AMOTL2 by the mTORC2 kinase promotes YAP
signaling, resulting in enhanced glioblastoma growth and
invasiveness. J Biol Chem. 290:19387–19401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gallant P and Steiger D: Myc's secret life
without Max. Cell Cycle. 8:3848–3853. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pérez-Sayáns M, Suárez-Peñaranda JM,
Padín-Iruegas E, Gayoso-Diz P, Reis-De Almeida M, Barros-Angueira
F, Gándara-Vila P, Blanco-Carrión A and García-García A:
Quantitative determination of c-myc facilitates the assessment of
prognosis of OSCC patients. Oncol Rep. 31:1677–1682. 2014.
View Article : Google Scholar : PubMed/NCBI
|
